

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bioengine Capital Inc.</u> (Last) (First) (Middle) 7TH FL., NO.3-2, PARK ST., NANGANG DIST. (Street) TAIPEI CITY F5 11503 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/21/2018	3. Issuer Name and Ticker or Trading Symbol <u>WINDTREE THERAPEUTICS INC /DE/ [WINT]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK	3,551,750	D ⁽¹⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
SERIES F WARRANTS	12/24/2018	06/24/2020	COMMON STOCK 384,824	3.68	D ⁽²⁾	
SERIES G WARRANTS	12/24/2018	12/24/2023	COMMON STOCK 747,012	4.05	D ⁽³⁾	

1. Name and Address of Reporting Person* <u>Bioengine Capital Inc.</u> (Last) (First) (Middle) 7TH FL., NO.3-2, PARK ST., NANGANG DIST. (Street) TAIPEI CITY F5 11503 (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>Center Laboratories, Inc.</u> (Last) (First) (Middle) 7TH FL., NO.3-2, PARK ST., NANGANG DIST. (Street) TAIPEI CITY F5 11503 (City) (State) (Zip)		
---	--	--

Explanation of Responses:

- The shares are directly held by Bioengine Capital Inc. and indirectly held by Center Laboratories, Inc., which owns 58.6% of Bioengine Capital Inc.
- The exercisable shares of Series F Warrants will be directly held by Bioengine Capital Inc. and indirectly held by Center Laboratories, Inc.
- The exercisable shares of Series G Warrants will be directly held by Bioengine Capital Inc. and indirectly held by Center Laboratories, Inc.

/s/ Lin, Jung-Chin

03/21/2019

/s/ Lin, Jung-Chin

03/21/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

**** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.